Medrysonum

Medrysonum Uses, Dosage, Side Effects, Food Interaction and all others data.

Medrysonum is a corticosteroid used in ophthalmology.

Medrysonum is a topical anti-inflammatory corticoidsteroids for ophthalmic use. In patients with increased intraocular pressure and in those susceptible to a rise in intraocular pressure, there is less effect on pressure with medrysone than with dexamethasone or betamethasone. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation.

Medrysonum
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Medrysonum
Generic	Medrysone
Medrysone Other Names	Medrisona, Medrysone, Medrysonum
Type
Formula	C₂₂H₃₂O₃
Weight	Average: 344.4877 Monoisotopic: 344.23514489
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Medrysonum is a topical glucocorticoid applied ophthalmically for the treatment of various ocular inflammatory or allergic conditions.

For the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.

Medrysonum is also used to associated treatment for these conditions: Conjunctivitis allergic, Conjunctivitis, Vernal, Epinephrine Sensitivity, Episcleritis

How Medrysonum works

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, the drug binds to the glucocorticoid receptor in the cytosol. This migrates to the nucleus and binds to genetic elements which cause activation and repression of the involved genes in the inflammatory pathway.